Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VS vs VRAX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VRAX Captures Overall Composite Edge (46.5 HOLD vs 40.6 SELL), While VS Leads 3–1 on Growth & Valuation Pillars

VRAX Overall Winner 6-Pillar Tally: VS 3 – 1 VRAX (2 Tie) Matrix Metrics: VS 3 – 4 VRAX

As of Nov 20, 2026, Virax Biolabs Group Limited (VRAX) captures the overall head-to-head institutional edge over Versus Systems Inc. (VS) on higher Unified Composite conviction (46.5/100 HOLD vs. 40.6/100 SELL) after splitting the core matrix 4–3 (led by Growth & Scale), while VS wins 3–1 across the 6-pillar growth and valuation breakdown. VS trades at $0.57 (N/M Forward P/E, -136.2% operating margin) versus VRAX at $0.33 (N/M Forward P/E, -51515.2% operating margin).

  • Growth vs. Quality Trade-Off: VRAX earns the overall head-to-head edge with a stronger Unified Composite Score (46.5/100 HOLD vs. VS 40.6/100 SELL) and -8.20β · 162% Vol risk profile, whereas VS leads top-line expansion (-24.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.7); meanwhile VRAX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VS vs VRAX
VS NASDAQ
Versus Systems Inc. Common Stock
Services-Computer Processing & Data Preparation
$0.57
-17.44% 1D
Market Cap $4.3M
TTM Revenue $1.5M
Forward P/E N/M
Beta / 30D Vol 1.45β · 78% Vol
Unified Composite Score
40.6 / 100 SELL
Tech 25.0 Fund 47.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.0%), weak momentum, RSI 24
RSI-14: 23.7 · SMA20: $0.80 · SMA50: $0.95
VRAX NASDAQ Head-to-Head Winner
Virax Biolabs Group Limited Ordinary Shares
In Vitro & In Vivo Diagnostic Substances
$0.33
-12.89% 1D
Market Cap $470,745
TTM Revenue $12,423
Forward P/E N/M
Beta / 30D Vol -8.20β · 162% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 45.0 Fund 50.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -33.8%), weak momentum, RSI 17
RSI-14: 17.3 · SMA20: $0.84 · SMA50: $1.56

6-Pillar Scorecard Institutional Category Breakdown (VS 3 – 1 VRAX)

Columns: Metric · VS · VRAX
1. Valuation Multiples VS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 2.8x 37.9x
2. Growth & Scale VRAX
Revenue Growth (YoY) -24.7% +684.9%
Earnings Growth (YoY) -30.4% +0.0%
TTM Revenue (USD) $1.5M $12,423
Market Cap $4.3M $470,745
3. Profitability & Quality VS
Gross Margin 100.0% 61.9%
Operating Margin -136.2% -51515.2%
Net Profit Margin -112.8% 0.0%
Return on Equity (ROE) -69.2% -78.6%
4. Balance Sheet & Cash Flow VS
Cash Generation (TTM) -$2.2M -$6.0M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.82 Book/Sh · -69.2% ROE $13.08 Book/Sh · -78.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Software - Application Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VS (3) vs VRAX (4)
Institutional Metric VS VRAX Criterion Row Edge
Market Capitalization
Scale
$4.3M $470,745 Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-24.7% +684.9% Higher Growth VRAX
Operating Margin (TTM)
Profitability
-136.2% -51515.2% Higher Margin VS
Net Profit Margin
Profitability
-112.8% 0.0% Higher Margin VRAX
Return on Equity (ROE)
Capital Efficiency
-69.2% -78.6% Higher ROE VS
52-Week Range Position
Momentum
0% ($1–$2) 2% ($0–$13) Stronger Trend VRAX
Beta / 30D Volatility
Risk Regime
1.45β · 78% Vol -8.20β · 162% Vol Lower Realized Risk VS
Unified Institutional Score
Composite Signal
40.6 / 100 (SELL) 46.5 / 100 (HOLD) Higher Composite VRAX
Trailing 12M Revenue (USD)
Operating Scale
$1.5M $12,423 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 61.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.8x EV/Rev N/M PEG · 37.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.2M ($1.82 Book/Sh · -69.2% ROE) -$6.0M EBITDA ($13.08 Book/Sh · -78.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VS +32.3 pp
VS: -40.83% · VRAX: -73.13%
3M Horizon VS +32.82 pp
VS: -56.12% · VRAX: -88.94%
6M Horizon VRAX +66.28 pp
VS: -46.68% · VRAX: +19.6%
1Y Horizon VRAX +34.92 pp
VS: -59.54% · VRAX: -24.62%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VS vs VRAX. Trailing 12-month operating profitability (VS -136.2% vs VRAX -51515.2%) and valuation multiples (VS N/M vs VRAX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.5M
Gross Margin100.0%
Op. Margin-136.2%
ROE / Fwd P/E-69.2% · N/M
VRAX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$12,423
Gross Margin61.9%
Op. Margin-51515.2%
ROE / Fwd P/E-78.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VRAX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VRAX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VS Moat Profile Cyclical / Execution-Driven Positioning
Software - Application Operator
Competes within the Software - Application value chain with $4.3M market capitalization and -136.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VRAX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $470,745 market capitalization and -51515.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VS vs VRAX Key Questions & Quantitative Answers

As of Nov 20, 2026, Virax Biolabs Group Limited (VRAX) captures the overall head-to-head institutional edge over Versus Systems Inc. (VS) on higher Unified Composite conviction (46.5/100 HOLD vs. 40.6/100 SELL) after splitting the core matrix 4–3 (led by Growth & Scale), while VS wins 3–1 across the 6-pillar growth and valuation breakdown. VS trades at $0.57 (N/M Forward P/E, -136.2% operating margin) versus VRAX at $0.33 (N/M Forward P/E, -51515.2% operating margin). Growth vs. Quality Trade-Off: VRAX earns the overall head-to-head edge with a stronger Unified Composite Score (46.5/100 HOLD vs. VS 40.6/100 SELL) and -8.20β · 162% Vol risk profile, whereas VS leads top-line expansion (-24.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.7); meanwhile VRAX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VRAX leads the Growth & Scale pillar: VS posts -24.7% YoY revenue growth and -30.4% YoY earnings growth on $1.5M TTM revenue (100.0% gross margin, -136.2% operating margin), compared with VRAX at +684.9% YoY revenue growth and +0.0% YoY earnings growth on $12,423 TTM revenue (61.9% gross margin, -51515.2% operating margin). On trailing 12-month operating scale, VS generates $1.5M in USD-normalized revenue versus $12,423 for VRAX. In operating R&D and SG&A reinvestment, VS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VRAX.

VS screens cheaper on headline valuation multiples. VS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.8x EV/Revenue (unreported FCF margin), whereas VRAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 37.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VS (-69.2% ROE) versus VRAX (-78.6% ROE) capital efficiency.

In options market volatility and institutional positioning, VS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.45β · 78% Vol realized risk). By comparison, VRAX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-8.20β · 162% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.